The central inflammatory cytokines involved are Tumor Necrosis Factor-α (TNF-α), IL-1β, and IL-6, targeted by biotechnological drugs that have dramatically improved the prognosis of patients with RA unresponsive to conventional disease-modifying antirheumatic drugs (DMARDs) therapy. Here, TNF is linked to rheumatoid arthritis.